Navigation Links
Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College
Date:1/14/2014

VALHALLA, N.Y., Jan. 14, 2014 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the relocation of its corporate headquarters to Valhalla, NY as of January 15, 2014 and expanded lease agreement for additional laboratory space at New York Medical College.

Oligomerix, which is focused on the development of small molecule drugs aimed specifically at inhibiting tau aggregation at the earliest steps of tau self-association into toxic oligomers in neurons, has continued to successfully advance its research, resulting in the need to add staff and expand its office and lab space.

"We're extremely encouraged by the preclinical data we've observed in our lead small molecule program, and are eager to continue our research in this space," stated James Moe, Ph.D., MBA, President and CEO of Oligomerix.  "As New York Medical College is already providing space for in vivo mouse studies for our lead compound, we believe the decision to move and expand Oligomerix's corporate headquarters will benefit the company's logistical needs."

Oligomerix recently announced the appointment of James Hendrix, Ph.D., as the company's Senior Director of Chemistry, and plans to potentially recruit up to five employees in 2014.

ABOUT OLIGOMERIXOligomerix, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. Founded in 2006, the Company is headquartered in Valhalla, NY and is carrying out its in vivo studies at New York Medical College.  The Company is seeking strategic partners to help accelerate these exciting programs.  For more information, visit www.oligomerix.com.

Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services. CONTACTS: Oligomerix, Inc.  7 Legion Drive, Valhalla, NY

Tiberend Strategic Advisors, Inc. Jack Pasini 

Andrew Mielach  Chief Commercial Officer 

212-375-2694 917-912-4088

amielach@tiberend.com  jpasini@oligomerix.com 


'/>"/>
SOURCE Oligomerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimers Disease Progression
2. Ultragenyx Relocates Company Headquarters to Support Operational Expansion
3. ImmusanT Relocates Offices to State-of-the-Art Innovation Facility
4. Sysmex America Relocates Corporate Headquarters
5. HemoShear Relocates and Expands Operations to Historic Martha Jefferson Property in Charlottesville, Virginia
6. Growth Fuels Expansion As PendoTECH Relocates New Jersey Headquarters
7. Optimal Radiology Relocates Headquarters to Nashville
8. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
9. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
10. Survey Shows eContent Critical to Corporate Strategies
11. Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... Flight Network and PeaceHealth Oregon Network announced they renewed a ... efficiency for patients at hospitals in Eugene ... , and Florence, Oregon , who ... work collaboratively to move patients who require the highest level ... emergency exists. PeaceHealth ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
(Date:7/31/2017)... , July 31, 2017 Three Tru-D SmartUVC ... South Korea . Tru-D, short for "Total Room Ultraviolet ... operating rooms after an environmental services (ES) professional cleans the area with ... ... "Although the BAACH ...
Breaking Medicine Technology:
(Date:8/16/2017)... Lewisville, TX (PRWEB) , ... August 16, 2017 , ... ... in the United States, named Dr. Douglas J. Harrison, as the new Medical Director ... will be the new facility Medical Director of our Sienna Plantation location,” said Dr. ...
(Date:8/16/2017)... ... ... Every Chain”: an inspirational story for those shackled by the chains of a broken life. ... a writer and a woman of great faith and wisdom. She is a great ... was born and raised in Vero Beach, Florida and has dedicated her life and ministry ...
(Date:8/15/2017)... ... August 15, 2017 , ... The first study to report that overall ... been completed, with the team’s findings now published online ahead of print in the ... the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, was principal investigator ...
(Date:8/15/2017)... ... ... Progressive Dental, a leading dental marketing and consulting firm founded in ... Growing Companies in Tampa Bay. The Tampa Bay Business Journal creates this list considering ... growth. For this year’s award, Progressive Dental ranked number 29, with a percentage growth ...
(Date:8/15/2017)... ... August 15, 2017 , ... Dr. ... a patient’s periodontal disease . This information can be used to develop ... endpoint. , The two salivary diagnostic tests, named MyPerioPath® and MyPerioID® are offered ...
Breaking Medicine News(10 mins):